EZH2 mutational status predicts poor survival in myelofibrosis - Guglielmelli, Paola; Biamonte, Flavia; Score, Joannah; Hidalgo-Curtis, Claire; Cervantes, Francisco; Maffioli, Margherita; Fanelli, Tiziana; Ernst, Thomas; Winkelman, Nils; Jones, Amy V.; Zoi, Katerina; Reiter, Andreas; et al. (Blood, 2011)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Disease-Free Survival; DNA-Binding Proteins - genetics; Enhancer of Zeste Homolog 2 Protein; Exons; Female; Hematologic and hematopoietic diseases; Heterozygote; Humans; Janus Kinase 2 - genetics; Kaplan-Meier Estimate; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Mutation; Mutation, Missense; Polycomb Repressive Complex 2; Polycythemia Vera - etiology; Polycythemia Vera - genetics; Primary Myelofibrosis - complications; Primary Myelofibrosis - genetics; Prognosis; Repressor Proteins - genetics; Thrombocythemia, Essential - etiology; Thrombocythemia, Essential - genetics; Transcription Factors - genetics; Young Adult; Histone-lysine N-methyltransferase; Myelofibrosis; Hematology; Enzyme; Transferases; Transcription repressor; Hemopathy; Survival; Myeloproliferative syndrome; Methyltransferases; Ezh2 gene; Genetics; Mutation; Predictive factor